CytRx Identifies RNAi Drug Candidate for Animal Testing, CEO Downplays Significance of Suits | GenomeWeb

CytRx announced last week that it will advance an siRNA into animal studies as a treatment for type II diabetes and obesity, marking the first time the company has decided to pursue in vivo testing of an RNAi drug candidate.

Separately this week, CytRx President and CEO Steven Kriegsman downplayed the significance of two lawsuits filed against him recently in relation to his one-time directorship of software firm AuthentiDate, stating that the suits have no impact on CytRx.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.